Prelude Therapeutics (PRLD) just unveiled an update.
Prelude Therapeutics Incorporated has announced a change in their financial leadership, with CFO Laurent Chardonnet stepping down. Although no longer CFO as of April 8, 2024, Chardonnet will continue to provide consulting services to the company until October 4, 2024. He will receive severance pay equivalent to nine months of his base salary, in addition to other benefits. Subsequently, Bryant D. Lim, previously Chief Legal Officer and Corporate Secretary, has been named the interim CFO while the company searches for a permanent replacement. Lim brings a wealth of legal and compliance experience from the biotechnology industry to his new dual role.
See more data about PRLD stock on TipRanks’ Stock Analysis page.
